Hints and tips:
...Boston Scientific and Edwards Lifesciences, both of which have large cardiovascular businesses, command an average multiple of around 22....
...Many Indian entrepreneurs have been slowing organic expansion at home and boosting foreign buyouts, such as UPL Corp’s takeover of US-based Arysta LifeScience....
...Though Campbell did not have a technical background — neither did Steve Jobs, his friends point out — in 1987 he set up Claris, an Apple-backed software company, which he ran for several years before it...
...The Aim-listed stock fell 13 per cent on Monday after the company ended an agreement with Arysta LifeScience to develop and sell treatments in the US combining PHC’s protein technology for improving crop...
...Edwards Lifesciences Corp rose 1.87 per cent to close at $145.12. Genworth Financial and Western Digital Corp shed last week’s gains, falling 3.36 per cent to $7.48 and 1.30 per cent to $79.82....
...Backed by Bill Ackman’s Pershing Square hedge fund, Platform Speciality has in the past year added to its portfolio Arysta LifeSciences for $5.4bn, and OM Group for $365m....
...Platform Specialty Products, the company backed by activist investor Bill Ackman, has agreed to buy Arysta LifeScience in a deal valuing the Irish agriculture chemical maker at $3.51bn, including debt....
...device maker received an unfavourable ruling from a federal court in Delaware banning it from selling its aortic heart valve replacement system, which was earlier found to infringe a patent by rival Edwards Lifesciences...
...Stuart’s early career began at Oracle and he has worked on major data and information initiatives for companies including United Healthcare Group, Edwards Lifesciences and most recently Spectrum Pharmaceuticals...
...capacities including, variously, chairman, chief executive, committee chair, senior adviser and board member of pharmaceutical, life sciences and investment companies such as GlaxoSmithKline, Allergan Inc...
...Edwards Lifesciences tumbled 21.2 per cent to $84.6, making it the worst-hit stock on the S&P 500, after the cardiovascular equipment maker warned that third-quarter revenues would be lower than expected...
...Edwards Lifesciences tumbled 14 per cent to $92.30 in after-market trading as the maker of cardiovascular equipment said sales for the third quarter would fall short of market expectations....
...Permira’s last deal, the Y100bn acquisition of Tokyo-based Arysta LifeScience in October 2007, was another secondary buyout, from a Hong Kong-based investment group....
...Edwards Lifesciences climbed 5.1 per cent to $67.85, on the back of upgrades from several analysts. A Morgan Keegan noted pointed to the group’s strong product pipeline and prospects in China....
...Siemens has 4 per cent, but the most interesting investor is Edwards Lifesciences, world market leader in heart valves, which is quoted on the New York Stock Exchange with a market capitalisation of $8bn...
...Edwards LifeSciences tumbled after the administrator of the government’s Medicare and Medicaid programmes dealt a blow to hopes of a rapid roll-out for its new cardiovascular device....
...Other groups that have sealed partnerships include GlaxoSmithKline with Dr Reddy’s Laboratories, and Pfizer with Aurobindo and Claris Lifesciences....
...Mr Berruyer, who trained as an engineer at the Ecole Polytechnique Fédérale de Lausanne and holds an MBA from Harvard, has held roles at US software group Intuit, Groupe Bull of France and Claris....
...Lifesciences....
...Edwards Lifesciences dropped 4.9 per cent to $52.15 as Goldman Sachs cut its recommendation on the company, which is focused on developing treatments for cardiovascular diseases, from “buy” to “neutral”...
...Aurobindo will provide it with the rights to market 60 generic drugs in 70 countries, and Claris Lifesciences with 15 injectable medicines....
...Pfizer, by contrast, has so far opted for partnerships, agreeing to license medicines from Aurobindo and Claris Life Sciences in India, as did GSK with Aspen in South Africa....
...Aurobindo will provide it with the rights to market 60 generic drugs in 70 countries, and Claris Lifesciences with a further 15 injectable medicines....
...In a little-noticed deal that was sealed last week, New Silk Route, a New York-based growth capital firm, paid about $50m for a nearly 30 per cent interest in Nectar Lifesciences, an Indian generics company...
...James Coffin, who heads Dell’s Healthcare and Lifesciences business, compares it to the evolution of financial services....
International Edition